|
|
|
|
|
|
|
|
|
|
abstract
Expert opinion: Despite the large number of data from Phase III trials about cardiac events incidence, there are poor evidences for detection, monitoring and management of cardiotoxicity during BC treatment. Future cardiotoxicity-oriented clinical cancer research can help to predict the risk of cardiac adverse events and improve patients’ outcome. Multidisciplinary approach as well as integration of blood biomarkers with imaging will be desirable.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.